|Articles|November 18, 2003
FDA approves CrystaLens, first accommodating IOL
Eyeonics inc. (formerly C&C Vision) received FDA approval to marketthe CrystaLens, the first accommodating IOL that allows patients to focusautomatically and seamlessly at all distances.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Kodiak Sciences releases follow-up, 20-week data from APEX study
2
Opus Genetics has Type B RMAT meeting with FDA for its gene therapy candidate, OPGx-LCA5
3
From then to next: Five decades of transformation in ophthalmology
4
PolyActiva and RareSight partner to develop treatments for rare pediatric retinal diseases
5














































.png)


